Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension-Reference-Cited by-同舟云学术

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension

Published:2015-09-14 Issue:12 Volume:17 Page:1142-1149
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Yki‐Järvinen H.¹²,Bergenstal R. M.³,Bolli G. B.⁴,Ziemen M.⁵,Wardecki M.⁶,Muehlen‐Bartmer I.⁵,Maroccia M.⁷,Riddle M. C.⁸

Affiliation:

1. Division of Diabetes, Faculty of Medicine University of Helsinki, Helsinki University Central Hospital Helsinki Finland

2. Minerva Foundation Institute for Medical Research Helsinki Finland

3. International Diabetes Center at Park Nicollet Minneapolis MN USA

4. Department of Medicine University of Perugia Perugia Italy

5. Sanofi‐Aventis Deutschland GmbH Frankfurt am Main Germany

6. Sanofi Warsaw Poland

7. Umanis Levallois‐Perret France

8. Division of Endocrinology, Diabetes & Clinical Nutrition Oregon Health & Science University Portland OR USA

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12532

Reference17 articles.

1. New insulin glargine 300 units.mL‐1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units.mL‐1;Becker RH;Diabetes Care,2015

2. Barriers to insulin initiation and intensification and how to overcome them

3. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

4. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3)

5. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study;Diabetes, Obesity and Metabolism;2024-07-29

2. A dose titration protocol for once‐daily insulin glargine 300 U/mL for the treatment of diabetes mellitus in dogs;Journal of Veterinary Internal Medicine;2024-06-03

3. Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials;Frontiers in Endocrinology;2024-03-21

4. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study;Advances in Therapy;2024-03-21

5. The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective;Journal of Medical Economics;2023-11-11